10 Buzzing AI Health Stocks 

Page 4 of 10

7. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders: 61 

Bristol-Myers Squibb Company (NYSE:BMY) is a New York-based pharmaceutical company. The firm has integrated AI in its drug discovery and development pipeline. The company’s AI-driven tools help accelerate research by analyzing complex biological data and identifying potential drug candidates for diseases such as cancer and cardiovascular conditions. The drugmaker has also used AI to optimize its clinical trials, reducing the time and cost of bringing new therapies to market.

In the second quarter of 2024, the firm posted more than $12.2 billion in revenue, a 8.69% increase year-over-year. For the twelve months leading up to July, the revenue was over $46.5 billion, a 2.93% increase year-over-year. The company’s oncology segment, bolstered by AI-powered drug development, contributed significantly to this growth. AI is expected to play a larger role in Bristol-Myers’ future earnings as the company continues to invest in AI-enhanced therapeutic research and development.

Page 4 of 10